Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/26/23 → 10/26/25 |
Funding
- BeiGene USA Incorporated: $33,365.00
23-HN-38-BG(BGB-HNSCC-201):A Phase 2, Randomized, Open-label, multi-arm Study of Tislelizumab in Combination with Investigational Agents as First Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Arnold, Susanne M (PI)